Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
TargetGene Biotechnologies
Rishon LeZion, Israel
B
1-10 Employees
2012
Key takeaway
TargetGene is dedicated to developing a leading therapeutic genome editing platform, positioning itself as a key player in the therapeutics arena, which is highly relevant to in vivo gene therapy.
Reference
Core business
TARGETGENE – DEVELOPING THE WORLD’S BEST THERAPEUTIC GENOME EDITING PLATFORM
EdiTy Therapeutics
Ness Ziona, Israel
B
1-10 Employees
2020
Key takeaway
Edity Therapeutics is pioneering in vivo gene therapy by utilizing immune cells to deliver therapeutic proteins directly to the cytoplasm of diseased cells. This innovative approach aims to reprogram cells and tissues to promote healing, offering potential treatments for various conditions, including oncology and genetic diseases.
Reference
Core business
Home - Edity Therapeutics
Edity Therapeutics - Cellular Re-programming utilizing the Immune system: We use immune cells to deliver protein directly to the cytoplasm of diseased cells to improve patient health and longevity.
IntraGel Therapeutics
Nazareth, Israel
B
1-10 Employees
2021
Key takeaway
Intragel is focused on innovating safe and effective treatments for life-threatening solid tumors through its advanced SRGel drug delivery system, which enhances the release and efficacy of anticancer medications.
Reference
Core business
Intragel – Continuous Smart Therapy
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
QR Genetics
Tel-Aviv, Israel
B
1-10 Employees
2019
Key takeaway
QRGenetics is focused on developing precision medicine for genetic diseases, leveraging an AI drug-discovery engine that identifies novel drug targets. This approach may lead to new therapeutic applications, which could be relevant for in vivo gene therapy advancements.
Reference
Core business
A drug development engine for genetic diseases A drug development engine for genetic diseases
1E Therapeutics
Rishon LeZion, Israel
B
51-100 Employees
2020
Key takeaway
1E Therapeutics is pioneering a new class of programmable oligonucleotide therapeutics that have the potential to revolutionize in vivo gene therapy by precisely silencing disease-causing RNAs in human or pathogen cells. Their innovative approach addresses a wide range of diseases, highlighting the promise of therapeutic RNA silencing.
Reference
Core business
The future of therapeutic RNA silencing
Immunovative Therapies Ltd.
Jerusalem, Israel
B
11-50 Employees
2004
Key takeaway
Mirror Biologics, Inc. specializes in developing innovative immunotherapy products, including their lead product, AlloStim®, which utilizes living immune cells to create a customized immune response. Their advanced Mirror Effect® technology platform enhances the ability to re-program immune responses, offering potential solutions for cancer treatment and viral infections, aligning with the principles of in vivo gene therapy by targeting the body's immune system directly.
Reference
Core business
Vaccines | Mirrorbio
Mirror Biologics, Inc. (“MBI”) is an international biopharmaceutical company specialized in development and manufacturing of next generation immunotherapy products where the active ingredients are living immune cells. www.mirrorbio.com
SBI Japan-Israel Innovation Fund
Herzliya, Israel
B
- Employees
2017
Key takeaway
LogicBio is actively involved in innovative gene therapy and gene editing technologies aimed at curing serious, early-onset rare diseases.
Reference
Core business
Home | SBIJI
NanoGhost
Netanya, Israel
B
11-50 Employees
2019
Key takeaway
NanoGhost is a biotech company that focuses on developing a targeted drug delivery platform using Nano-Ghosts derived from mesenchymal stem cells (MSCs), which have a natural ability to home in on cancer and inflammation sites. This innovative approach may have implications for enhancing the effectiveness of in vivo gene therapy.
Reference
Core business
NanoGhost | Targeted Drug Delivery Platform | Home
NanoGhost is a biotech company that develops a highly selective first-in-class drug delivery platform (Nano-Ghosts/NGs) from the cell membrane of mesenchymal stem cells (MSCs), cells with known tropism to cancer and sites of inflammation.
ADVA Biotechnologies
Haifa, Israel
B
11-50 Employees
2016
Key takeaway
Adva Biotechnology is focused on revolutionizing cell therapy manufacturing through its innovative ADVA platform, which enhances autologous cell therapy processes. Their commitment to advanced therapies aligns with the growing field of in vivo gene therapy.
Reference
Core business
Home // AdvaBio
VALUING LIFE Granting Advanced Therapies to Patients Automated Autologous Cell Manufacturing Platform Adva Biotechnology introduces the ADVA platform, a fully controlled, flexible, and automated cell processing platform. The system provides a solution to autologous cell therapy manufacturing processes using the unique CAMP (Continues Adaptive Multi-Parameter) technology.
Entera Bio
Jerusalem, Israel
B
11-50 Employees
2010
Key takeaway
The company, EnteraBio, is focused on developing innovative oral delivery systems for protein and peptide replacement therapies. Their approach aims to significantly improve treatment outcomes for patients with chronic diseases by providing an injection-free alternative.
Reference
Core business
Home - EnteraBio
We are a clinical stage, global company, focused on high unmet clinical needs where oral delivery of a protein therapy can significantly improve the standard of care. We are developing first-in-class, daily tablet protein and peptide replacement therapies, designed for patients to live healthier and injection-free, as they manage their chronic diseases. Our goal is for our small, oral protein tablets to change treatment outcomes for patients globally.
Technologies which have been searched by others and may be interesting for you:
When exploring the In Vivo Gene Therapy industry in Israel, several key considerations come into play. The regulatory landscape is crucial, as the Israeli Ministry of Health oversees gene therapy practices, ensuring compliance with strict guidelines. Challenges in this sector often include securing funding for research and development, as well as navigating the complexities of clinical trials, which are essential for bringing new therapies to market. Opportunities are abundant due to Israel's strong emphasis on biotechnology and innovation, supported by a robust network of research institutions and universities. The competitive landscape features both established companies and startups, fostering a dynamic environment for collaboration and technological advancement. Additionally, global market relevance is significant, as Israeli firms often engage in international partnerships, leveraging their expertise to address global health issues. Environmental concerns also play a role, as companies must consider the ecological impact of gene therapy practices and adhere to sustainable practices. Overall, an understanding of these factors can provide valuable insights for anyone interested in the In Vivo Gene Therapy industry in Israel, highlighting both the potential for growth and the challenges that lie ahead.
Some interesting numbers and facts about your company results for In Vivo Gene Therapy
| Country with most fitting companies | Israel |
| Amount of fitting manufacturers | 197 |
| Amount of suitable service providers | 56 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 2004 |
| Youngest suiting company | 2021 |
Some interesting questions that has been asked about the results you have just received for In Vivo Gene Therapy
What are related technologies to In Vivo Gene Therapy?
Based on our calculations related technologies to In Vivo Gene Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of In Vivo Gene Therapy?
Start-Ups who are working in In Vivo Gene Therapy are IntraGel Therapeutics
Which industries are mostly working on In Vivo Gene Therapy?
The most represented industries which are working in In Vivo Gene Therapy are Medical, Other, Biotechnology, Pharmaceuticals, Healthcare
How does ensun find these In Vivo Gene Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.